RE: Americans20 Oct 2020 23:44
If any of our American cousins are reading this group chat and are unsure, I think I'm right in saying:
- Accustem had zero balance sheet value this Summer
- It's been proven 45% better than Oncotype DX, bout by Exact for $2.8 billion
- Post the UK and Italian trials, a US investment firm (Wainwright?) has valued this element of TILS's business at $280 million
- the court hearing this week placed a Company value of £4 million ($5.17 million) for the Accustem spin off
- the shares will be unlised after end of October, with UK listing due Nov / Dec 2020
- the plan is for Nasdaq to follow
- every 2 ADR's is equivalent to 1 share. I guess US investors will be allocated on this London basis (but not been specified)
- As soon as the London listing is approved, US investors can buy more London listed shares
Now, if that doesn't sound like a great deal, please let me know. Also, please feel free to correct if I've typos or got the wrong end of the string.
GLA